We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Beneficial Mutation Dissociates Obesity from Diabetes

By LabMedica International staff writers
Posted on 23 Dec 2009
A potentially beneficial mutation has been identified that seems to dissociate obesity from the danger of developing type II diabetes.

Although some 20 to 30% of obese individuals fail to progress to diabetes, and while some nonobese individuals do develop the disease, the current report is perhaps the first to link these observation to the action of a specific gene.

Investigators at the Boston University School of Medicine (MA, USA) discovered a mutation of the Brd2 (Bromodomain-containing protein 2) gene in a population of laboratory mice. More...
These animals became severely obese but did not go on to develop type II diabetes. Specifically, reduced function of the Brd2 gene enhanced glucose tolerance; elevated adiponectin; increased the weight of brown adipose tissue; increased heat production and expression of mitochondrial uncoupling proteins in brown adipose tissue; reduced macrophage infiltration in white adipose tissue; and lowered blood glucose, leading to an improved metabolic profile and avoiding eventual type II diabetes.

These findings were published in the November 2, 2009, online edition of The Biochemical Journal (BJ) where the authors also noted that Brd2 was highly expressed in pancreatic beta cells, where it normally inhibits beta-cell mitosis and insulin transcription.

Senior author Dr. Gerald Denis, assistant professor of pharmacology and medicine at the Boston University School of Medicine, said, "Studies have shown that these individuals [obese but free of type II diabetes] have a reduced "inflammatory profile". Inflammation caused by normal immune cells called macrophages leads to insulin resistance and type II diabetes - this inflammation is typically seen in connection with obesity but it is the inflammation that is a trigger for diabetes, not the obesity itself. The mechanisms that explain this protection from diabetes are not well understood. Much like these protected obese humans, the Brd2-deficient mice have reduced inflammation of fat and never develop failure of the beta cells in the pancreas that is associated with type II diabetes."

"The strong influence of Brd2 levels on insulin production and action suggest that Brd2 is likely to be a promising target for diabetes treatment, but also imply that overactive Brd2 might cause diabetes," said Dr. Denis. "The ways in which Brd2 affects the immune system may also play a part in type I diabetes; further studies to determine this are needed."

Related Links:
Boston University School of Medicine



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.